계명대학교 의학도서관 Repository

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study

Metadata Downloads
Author(s)
Jung Hye KwonHo‑Jin ShinHyo Jung KimYong Rok DoCheolwon SuhHyo Jin KimMyeong Seok KohWon Seog KimSeok Jin KimSung Yong OhDok Hyun YoonSoon Il LeeJunshik HongMoo Kon Song
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
International Journal of Hematology
Issued Date
2015
Volume
102
Issue
4
Keyword
Marginal zoneB cell lymphomaChemotherapyLocal stage
Abstract
Even though local stage (Ann Arbor stage I/II) marginal zone lymphoma (MZL) is well controlled with local treatment-based therapy, no data exist on the role of additional chemotherapy after local treatment for stage I/II MZL. Patients with biopsy-confirmed Ann Arbor stage I/II MZL (n = 210) were included for analysis in this study. Of these, 180 patients (85.7 %) were stage I and 30 (14.3 %) were stage II. Most patients (n = 182, 86.7 %) were treated with a local modality including radiation therapy or surgery and 28 (13.3 %) received additional systemic chemotherapy after local treatment. The overall response rate was 98.3 % (95 % CI 96–100 %), with 187 complete responses and 20 partial responses. In the local treatment group, the mean progression-free survival (PFS) was 147.4 months (95 % CI 126.7–168.1 months) and the overall survival (OS) was 188.2 months (95 % CI 178.8–197.7 months). In the additional chemotherapy group, the mean PFS was 103.4 months (95 % CI 84.9–121.9 months) and the OS was 137.3 months (95 % CI 127.9–146.7 months). There was no difference between the two groups in OS (p = 0.836) and PFS (p = 0.695). Local stage MZL has a good clinical course and is well controlled with a local treatment modality without additional chemotherapy.
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine
Citation
Jung Hye Kwon et al. (2015). Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. International Journal of Hematology, 102(4), 420–425. doi: 10.1007/s12185-015-1845-6
Type
Article
ISSN
0925-5710
Source
http://lps3.dx.doi.org.proxy.dsmc.or.kr/10.1007/s12185-015-1845-6
DOI
10.1007/s12185-015-1845-6
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/32886
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.